04:23 AM EDT, 07/27/2026 (MT Newswires) -- Shares in AstraZeneca (AZN.L, AZN.ST) rose early Monday morning after the drugmaker posted higher first-half results and backed its full-year guidance and long-term targets. Attributable profit for the six months ended June 30 increased to $5.59 billion from $5.37 billion a year earlier, while revenue climbed to $30.67 billion from $28.05 billion. The revenue increase was helped by double-digit growth in the company's oncology and rare disease drugs, which mitigated headwinds from the loss of exclusivity for its Farxiga drug in the US and China volume-based procurement. AstraZeneca shares were up more than 1% in London during early morning trading and were marginally higher in Stockholm. "In the first half we saw strong performance and continued pipeline delivery, including six key positive Phase III [programs] and eight first approvals in major markets, including in the US for Baxfendy, our first-in-class medicine for hypertension," Chief Executive Pascal Soriot said. Looking ahead, the company maintained its full-year guidance of mid-to-high single-digit growth in total revenue, alongside a low-double-digit increase in core EPS. "While we are disappointed by the CARDIO-TTRansform outcome, we are on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks. We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months," Soriot added. The AstraZeneca board raised the interim dividend for the first half by $0.03 to $1.06 per share.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.